From DCAT Week 2023: Supplier News: Packaging
By

By
A roundup of news from CDMOs/CMOs and suppliers in pharmaceutical packaging with news from PCI Pharma Services, Bormioli, and Tedor Pharma Services. Highlights below.   * PCI Pharma Services Investing $50…

From DCAT Week 2023: Supplier News: End-to-End (Drug Substance and Drug Product) Mfg
By

By
A roundup of news from CDMOs/CMOs and suppliers in both drug-substance and drug-product development and manufacturing with news from CordenPharma and BioDuro Sundia. Highlights below.   * CordenPharma Expanding Peptide &…

From DCAT Week 2023: Supplier News: Biologics Manufacturing
By

By
A roundup of news from CDMOs/CMOs and suppliers in biomanufacturing, including advanced therapies, with news from BioVectra, Scorpius BioManufacturing, Avid Bioservices, IDT Biologika, Landmark Bio, and Mabion. Highlights below.   *…

From DCAT Week 2023: Supplier News: Chemicals/Chemical API Manufacturing
By

By
The latest news for CDMOs/CMOs and suppliers involved in the development and manufacturing of chemicals and chemical active pharmaceutical ingredients (APIs) with news from PharmaBlock, Seqens, Polpharma API, Cambrex, Actylis,…

From DCAT Week 2023: Supplier News: Formulation Development/Drug Product Manufacturing
By

By
The latest news from CMDOs/CMOs and suppliers involved in formulation development and drug-product manufacturing with news from Evonik, Carbogen Amcis, Vetter, Nanoform, Mikart, Ascendia Pharmaceuticals, Bushu Pharma, and Lifecore Biomedical.…

From DCAT Week: Kindeva Drug Delivery and Meridian Medical Technologies Merge To Create New Drug–Device CDMO 
By

By
A new drug–device CDMO, which merged Kindeva Drug Delivery (formerly 3M Drug Delivery Systems), a CDMO of drug-delivery services, and Meridian Medical Technologies, a Saint Louis, Michigan-based CDMO of autoinjectors,…

From DCAT Week: Porton Pharma Solutions Expanding Drug-Substance and Drug-Product Capacity 
By

By
Porton Pharma Solutions, a CDMO of active pharmaceutical ingredients (APIs) and drug products, is heavily investing in its drug-substance and drug-product research and manufacturing capacities. This includes expansions to current…

From DCAT Week: Thermo Fisher Scientific Outlines Multi-Segment Expansions 
By

By
Thermo Fisher Scientific is proceeding with a series of investments to expand capacity in cell and gene therapies, drug products, and biomanufacturing. Leon Wyszkowski, President of Commercial Operations, Pharma Services,…

From DCAT Week: WuXi Biologics’ Growing Global Footprint 
By

By
WuXi Biologics, a contract research, development, and manufacturing organization (CRDMO), continues to enhance its global manufacturing network by increasing its global capacity to meet growing clients needs around the world.…

From DCAT Week: Siegfried Expands Drug-Product and Small-Molecule API Capacity 
By

By
Siegfried, a CDMO of active pharmaceutical ingredients (APIs) and drug products, recently invested $190 million to expand its footprint in small-molecule and biopharmaceutical fill–finish capacity and capabilities. Marianne Späne, Executive…